Business, energy, technology, markets and global industry news from Business News Today

complex generics

PharmaDeviceNews complex generics
Representative image: Generic semaglutide injection pens on a clinical desk with Canadian healthcare cues, reflecting Dr. Reddy’s Laboratories’ launch of generic semaglutide injection in Canada and the growing focus on GLP-1 access for type 2 diabetes treatment.
Pharma & Biotech

Dr. Reddy’s moves first in Canada’s generic semaglutide market. Can access improve?

GLP-1 demand is booming, but access remains uneven. Dr. Reddy’s Canada launch tests whether generics can change semaglutide economics.

Read More
Representative image: A generic inhaler device in a clinical research setting, illustrating Transpire Bio’s FDA-accepted ANDA filing for a proposed generic high-strength Trelegy Ellipta alternative for asthma and COPD treatment.
Pharma & Biotech

What Transpire Bio’s Trelegy ANDA reveals about the next wave of inhaler competition

Trelegy is a blockbuster, but complex inhaler generics are closing in. Transpire Bio’s FDA filing could test GSK’s respiratory moat.

Read More
Representative image of sterile injectable medicine vials being reviewed in a hospital pharmacy setting, reflecting how Apotex’s generic Infuvite Pediatric Injection approval could expand access to pediatric parenteral nutrition and complex generic injectables in the United States.
Pharma & Biotech

How Apotex’s generic Infuvite pediatric approval could shift the sterile injectable multivitamin market

Pediatric nutrition needs reliable sterile supply. Apotex’s Infuvite generic approval tests whether complex generics can ease that gap.

Read More
Pharma & Biotech

Can Apotex crack the complex generic code for semaglutide before the glucagon-like peptide-1 market resets?

Apotex won first tentative U.S. approval for generic semaglutide. Read what it could mean for glucagon-like peptide-1 access, pricing, and competition.

Read More
Pharma & Biotech

DifGen Pharmaceuticals expands complex generics footprint with fluorometholone ophthalmic suspension approval

DifGen Pharmaceuticals secures rare FDA approval for fluorometholone ophthalmic suspension. Find out why this complex generic matters for ophthalmology markets.

Read More